1. Home
  2. IMCR vs TPB Comparison

IMCR vs TPB Comparison

Compare IMCR & TPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IMCR

Immunocore Holdings plc

HOLD

Current Price

$28.59

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Turning Point Brands Inc.

TPB

Turning Point Brands Inc.

HOLD

Current Price

$81.31

Market Cap

1.6B

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMCR
TPB
Founded
2008
1988
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Tobacco
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
2016
2015

Fundamental Metrics

Financial Performance
Metric
IMCR
TPB
Price
$28.59
$81.31
Analyst Decision
Buy
Buy
Analyst Count
10
3
Target Price
$66.33
$115.00
AVG Volume (30 Days)
432.7K
401.8K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
0.39%
EPS Growth
30.39
45.33
EPS
0.25
3.11
Revenue
$249,428,000.00
$463,062,000.00
Revenue This Year
$14.57
$13.68
Revenue Next Year
$8.21
$11.32
P/E Ratio
$114.16
$25.56
Revenue Growth
43.05
28.39
52 Week Low
$27.56
$65.80
52 Week High
$40.71
$146.90

Technical Indicators

Market Signals
Indicator
IMCR
TPB
Relative Strength Index (RSI) 49.22 43.43
Support Level $27.66 $66.94
Resistance Level $31.56 $84.94
Average True Range (ATR) 1.21 3.70
MACD 0.04 -0.50
Stochastic Oscillator 51.86 24.56

Price Performance

Historical Comparison
IMCR
TPB

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About TPB Turning Point Brands Inc.

Turning Point Brands Inc operates as a manufacturer, marketer, and provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum, including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments, namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.

Share on Social Networks: